Guardant ordered to pay TwinStrand damages

A U.S. court has issued a judgment in a DNA sequencing patent infringement case, ruling that Guardant Health (GH) is liable to TwinStrand Biosciences. The decision concludes a dispute over intellectual property related to DNA sequencing technology, with the court directing Guardant to pay a substantial monetary award to TwinStrand.

Reports describe the case as one focused on DNA sequencing patents, with TwinStrand positioned as the rights holder that prevailed at trial. The ruling assigns financial responsibility to Guardant following the finding of patent infringement, marking a clear legal win for TwinStrand in this lawsuit.

Coverage specifies that the court ordered Guardant to pay damages in an amount reported around $245 million. Several articles state that the award is $245 million, while at least one report cites the figure as $245.2 million. The different numbers indicate only a small discrepancy in published figures but consistently point to a large nine‑figure judgment.

Across the reports, the central point is that Guardant faces a significant financial obligation to TwinStrand as a result of the ruling. The size of the award underscores the value attributed to the DNA sequencing patents at issue and the financial impact of the court’s decision on the losing party.

While the judgment and approximate size of the award are clearly described, the articles provide little detail on procedural follow‑up. The available coverage does not specify whether Guardant has indicated plans to appeal the decision or to seek any post‑trial adjustments to the damages amount.

Similarly, there is no reported information on the timing or mechanism of payment from Guardant to TwinStrand, such as whether the damages would be paid in a lump sum or over time. The emphasis of the reporting remains on the fact of TwinStrand’s courtroom victory and the scale of the monetary award rather than on the case’s administrative or financial execution.

For TwinStrand Biosciences, the court’s decision represents a legal affirmation of its patent rights in the DNA sequencing area, coupled with a large associated damages award. The outcome highlights the role of patent enforcement in protecting technology assets in the life sciences sector.

For Guardant Health, the ruling creates a sizable financial liability tied directly to the patent claims adjudicated by the court. Although the broader strategic or operational responses by either company are not detailed in the reports, the judgment clearly establishes a material obligation for Guardant and a corresponding monetary gain for TwinStrand.